SCHEMBL10113653

SCHEMBL10113653

CCOC(=O)C1=C(C)N(C)C(=S)NC1c1cccc(Cl)c1Cl

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 1.00
L3MBTL1 Q9Y468 1/20 1.00
ALOX12 P18054 4/20 0.83
CYP2C9 P11712 4/20 0.83
CYP3A4 P08684 3/20 0.83
CYP2C19 P33261 3/20 0.83
HTT P42858 3/20 0.65
ALDH1A1 P00352 5/20 0.65
SMN1; SMN2 Q16637 2/20 0.59
CACNA1F O60840 1/20 0.57
CACNA1D Q01668 1/20 0.57
CACNA1S Q13698 1/20 0.57
CACNA1C Q13936 1/20 0.57
PKM P14618 1/20 0.54
MAPK1 P28482 1/20 0.54
POLB P06746 2/20 0.53
KDM4E B2RXH2 2/20 0.51
MEN1 O00255 2/20 0.51
CYP1A2 P05177 2/20 0.51
KMT2A Q03164 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10113621 0.89 LMNA (0.80) LMNAL3MBTL1ALOX12CYP2C9CYP3A4
SCHEMBL10113389 0.89 LMNA (0.80) LMNAL3MBTL1ALOX12CYP2C9CYP3A4
SCHEMBL10113090 0.79 ALOX12 (1.00) LMNAL3MBTL1ALOX12CYP2C9CYP3A4
SCHEMBL10113509 0.77 LMNA (0.62) LMNAL3MBTL1ALOX12CYP2C9CYP3A4
SCHEMBL14164071 0.76 POLB (0.79) LMNAL3MBTL1ALOX12CYP2C9CYP3A4
SCHEMBL4881545 0.76 LMNA (0.61) LMNAL3MBTL1ALOX12CYP2C9CYP3A4
SCHEMBL8199258 0.76 TSHR (0.73) LMNAL3MBTL1ALOX12CYP2C9CYP3A4
SCHEMBL7691927 0.75 ALDH1A1 (0.62) LMNAL3MBTL1ALOX12CYP2C9CYP3A4
SCHEMBL10280229 0.73 LMNA (0.57) LMNAL3MBTL1ALOX12CYP2C9CYP3A4
SCHEMBL10721631 0.72 TSHR (0.67) LMNAL3MBTL1ALOX12CYP2C9CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9815838-B2 Methods and compositions for treating pain HYDRA BIOSCIENCES, INC. (US) 2017-11-14 US disclosed
US-9815838-B2 Methods and compositions for treating pain HYDRA BIOSCIENCES, INC. (US) 2017-11-14 US disclosed
US-20140221401-A1 METHODS AND COMPOSITIONS FOR TREATING PAIN HYDRA BIOSCIENCES, INC. (US) 2014-08-07 US disclosed
US-20140221401-A1 METHODS AND COMPOSITIONS FOR TREATING PAIN HYDRA BIOSCIENCES, INC. (US) 2014-08-07 US disclosed
US-8389529-B2 Methods and compositions for treating asthma HYDRA BIOSCIENCES, INC. (US) 2013-03-05 US disclosed
US-8389529-B2 Methods and compositions for treating asthma HYDRA BIOSCIENCES, INC. (US) 2013-03-05 US disclosed
US-8178542-B2 Methods and compositions for treating pain HYDRA BIOSCIENCES, INC. (US) 2012-05-15 US disclosed
US-8178542-B2 Methods and compositions for treating pain HYDRA BIOSCIENCES, INC. (US) 2012-05-15 US disclosed
US-20120100609-A1 N-LINKED GLYCAN BIOSYNTHESIS MODULATORS BIOMARIN PHARMACEUTICAL INC. 2012-04-26 US disclosed
US-20100267750-A1 METHODS AND COMPOSITIONS FOR TREATING PAIN ELI LILLY AND COMPANY 2010-10-21 US disclosed
US-20100267750-A1 METHODS AND COMPOSITIONS FOR TREATING PAIN ELI LILLY AND COMPANY 2010-10-21 US disclosed
US-7671061-B2 Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence HYDRA BIOSCIENCES, INC. (US) 2010-03-02 US disclosed
US-7671061-B2 Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence HYDRA BIOSCIENCES, INC. (US) 2010-03-02 US disclosed
US-20070219222-A1 Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence HYDRA BIOSCIENCES (US) 2007-09-20 US disclosed
US-20070219222-A1 Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence HYDRA BIOSCIENCES (US) 2007-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120100609-A1 N-LINKED GLYCAN BIOSYNTHESIS MODULATORS ENGASE, GALNT1, GALNT13 LMNA 4109/4885L3MBTL1 1767/4885ALOX12 3011/4885
US-20100267750-A1 METHODS AND COMPOSITIONS FOR TREATING PAIN ACHE, COL2A1, MMP8 LMNA 1619/4885L3MBTL1 4639/4885ALOX12 66/4885
US-20070219222-A1 Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence TRPA1, TRPV1, TRPV2 LMNA 3299/4885L3MBTL1 3215/4885ALOX12 405/4885
US-20140221401-A1 METHODS AND COMPOSITIONS FOR TREATING PAIN ACHE, COL2A1, MMP8 LMNA 1619/4885L3MBTL1 4639/4885ALOX12 66/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.